Inovio Pharmaceuticals Inc.(INO) has potential to become corona-winner
Inovio Pharmaceuticals Inc.(INO) currently trades at $8.18 and has grown by 18.82% in the past 24 hours. Inovio Pharmaceuticals has already been in the race to develop a vaccine against COVID-19, with it claiming that it had designed its candidate, INO-4800, only three hours after Chinese researchers published the SARS-CoV-2 genetic sequence on January 10.
Based on this information, investorsQ rates this stock a 5 out of 10. We give it this rating because it received a $5 million grant from the Bill and Melinda Gates Foundation. Now, it’s grabbing headlines for another collaboration, and Wall Street is taking notice. The high forecast for Inovio Pharmaceuticals Inc. is $13 and the low is $7. Notably, the company’s market cap is $1.19 billion with a 52 week high of $19.36 and a 52 week low of $1.92.